Contributions
Abstract: P393
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Cognition is frequently impacted in people with Multiple Sclerosis (PwMS). Traditional evaluation of disease impact in PwMS by EDSS and MRI findings does not adequately identify/quantify cognitive impairment. MRI abnormalities in PwMS include demyelination, neuronal/axonal injury and atrophy. Quantitative analysis of MRI changes in PwMS is not commonly done in routine care. Investigating the relationship between regional atrophy measurements and multi-domain cognitive impairment might provide an important step to improved understanding of MS progression.
Objective: Explore the relationship between multiple individual cognitive domain scores, the number of impaired cognitive domains (#CDI), and the change in these individual approaches to analysis of cognitive function to specific regional brain atrophy measures as they both change over time in PwMS.
Methods: Retrospective review of PwMS who underwent both computerized cognitive screening battery (CAB-NT) at two different dates >1 year apart, and MRI performed < 3 months from each CAB-NT. A repeated measures analysis looked at correlations between 7 CAB-NT domains (global cognitive score, memory, executive function, visual-spatial (Vis), verbal function, attention, information processing speed, motor function, #CDI) with regional atrophy measurements [inter-caudate width -C, third ventricular width -TV, right thalamic width -RT, left thalamic width -LT right thalamic/cerebral peduncle width ratio -RTC, and left thalamic/cerebral peduncle ratio -LTC]. Significance was defined at p< 0.05.
Results: PwMS N=59, 81.4% female, average age = 47.3±10.7. VIS with RT p=0.02 and LT p=0.028; #CDI change correlated with change in RT volume p=0.009. Multiple individual cognitive domain scores as well as the change in these same cognitive domain scores individually over time did not correlate with a change in measured brain atrophy.
Conclusions: Change in #CDI is strongly correlated with the longitudinal change in degree of thalamic atrophy in PwMS. VIS is also significantly correlated with thalamic width bilaterally. GCS changes did not significantly correlate with any changes in regional atrophy measurements, supporting the notion that cognition is not a homogenous function and should not be solely measured with a single scale cognitive test. #CDI correlated with changes in thalamic volume, suggesting that change in cognitive network ability reflects both important structural changes and functional milestones.
Disclosure: *This study was supported by Genzyme, a Sanofi company*
EG: Nothing to disclose
KW: Nothing to disclose
Lf: Nothing to disclose
JS: Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva)
MB- Nothing to disclose
AG- Nothing to disclose
Abstract: P393
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Cognition is frequently impacted in people with Multiple Sclerosis (PwMS). Traditional evaluation of disease impact in PwMS by EDSS and MRI findings does not adequately identify/quantify cognitive impairment. MRI abnormalities in PwMS include demyelination, neuronal/axonal injury and atrophy. Quantitative analysis of MRI changes in PwMS is not commonly done in routine care. Investigating the relationship between regional atrophy measurements and multi-domain cognitive impairment might provide an important step to improved understanding of MS progression.
Objective: Explore the relationship between multiple individual cognitive domain scores, the number of impaired cognitive domains (#CDI), and the change in these individual approaches to analysis of cognitive function to specific regional brain atrophy measures as they both change over time in PwMS.
Methods: Retrospective review of PwMS who underwent both computerized cognitive screening battery (CAB-NT) at two different dates >1 year apart, and MRI performed < 3 months from each CAB-NT. A repeated measures analysis looked at correlations between 7 CAB-NT domains (global cognitive score, memory, executive function, visual-spatial (Vis), verbal function, attention, information processing speed, motor function, #CDI) with regional atrophy measurements [inter-caudate width -C, third ventricular width -TV, right thalamic width -RT, left thalamic width -LT right thalamic/cerebral peduncle width ratio -RTC, and left thalamic/cerebral peduncle ratio -LTC]. Significance was defined at p< 0.05.
Results: PwMS N=59, 81.4% female, average age = 47.3±10.7. VIS with RT p=0.02 and LT p=0.028; #CDI change correlated with change in RT volume p=0.009. Multiple individual cognitive domain scores as well as the change in these same cognitive domain scores individually over time did not correlate with a change in measured brain atrophy.
Conclusions: Change in #CDI is strongly correlated with the longitudinal change in degree of thalamic atrophy in PwMS. VIS is also significantly correlated with thalamic width bilaterally. GCS changes did not significantly correlate with any changes in regional atrophy measurements, supporting the notion that cognition is not a homogenous function and should not be solely measured with a single scale cognitive test. #CDI correlated with changes in thalamic volume, suggesting that change in cognitive network ability reflects both important structural changes and functional milestones.
Disclosure: *This study was supported by Genzyme, a Sanofi company*
EG: Nothing to disclose
KW: Nothing to disclose
Lf: Nothing to disclose
JS: Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva)
MB- Nothing to disclose
AG- Nothing to disclose